Giovanni Barosi

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 21

Top Topics

African American

Systematic Review

Acute Kidney Injury

Top Venues

Blood cancer journal

This page only lists publications with an associated author ORCID identifier.

Publications

Rita Campanelli, Adriana Carolei, Paolo Catarsi, Carlotta Abbà, Emanuela Boveri, Marco Paulli, Raffaele Gentile, Monica Morosini, Riccardo Albertini, Stefania Mantovani, Margherita Massa, Giovanni Barosi, Vittorio Rosti
Circulating Polymorphonuclear Myeloid-Derived Suppressor Cells (PMN-MDSCs) Have a Biological Role in Patients with Primary Myelofibrosis. Cancers 16 (14) (2024)
Giovanni Barosi, Rita Campanelli, Paolo Catarsi, Carlotta Abbà, Adriana Carolei, Margherita Massa, Robert Peter Gale, Vittorio Rosti
Type 1 CALR mutation allele frequency correlates with CD34/CXCR4 expression in myelofibrosis-type megakaryocyte dysplasia: A mechanism of disease progression? Blood cancer journal 14 (1) (2024)
Giovanni Barosi, Rita Campanelli, Paolo Catarsi, Carlotta Abbà, Adriana Carolei, Margherita Massa, Robert Peter Gale, Vittorio Rosti
Type 1 CALR mutation allele frequency correlates with CD34/CXCR4 expression in myelofibrosis-type megakaryocyte dysplasia: A mechanism of disease progression? Blood cancer journal 14 (1) (2024)
Ayalew Tefferi, Giovanni Barosi, Francesco Passamonti, Juan Carlos Carlos Hernández-Boluda, Prithviraj Bose, Konstanze Döhner, Martin Ellis, Naseema Gangat, Jacqueline S Garcia, Heinz Gisslinger, Jason Gotlib, Paola Guglielmelli, Vikas K Gupta, Claire N Harrison, Elizabeth O Hexner, Gabriela S Hobbs, Jean-Jacques Kiladjian, Steffen Koschmieder, Nicolaus M Kröger, Andrew T Kuykendall, Giuseppe Gaetano Loscocco, John O Mascarenhas, Lucia Masarova, Ruben A Mesa, Barbara Mora, Olatoyosi Odenike, Stephen T Oh, Animesh D Pardanani, Anand Ashwin Patel, Naveen Pemmaraju, Alessandro Rambaldi, Raajit K Rampal, Shireen Sirhan, Natasha Szuber, Moshe Talpaz, Pankit Vachhani, Alessandro M Vannucchi, Tiziano Barbui
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis. Blood (2024)
Giovanni Barosi, Rita Campanelli, Paolo Catarsi, Carlotta Abbà, Adriana Carolei, Margherita Massa, Robert Peter Gale, Vittorio Rosti
Type 1 CALR mutation allele frequency correlates with CD34/CXCR4 expression in myelofibrosis-type megakaryocyte dysplasia: A mechanism of disease progression? Blood cancer journal 14 (1) (2024)
Rita Campanelli, Adriana Carolei, Paolo Catarsi, Carlotta Abbà, Emanuela Boveri, Marco Paulli, Raffaele Gentile, Monica Morosini, Riccardo Albertini, Stefania Mantovani, Margherita Massa, Giovanni Barosi, Vittorio Rosti
Circulating Polymorphonuclear Myeloid-Derived Suppressor Cells (PMN-MDSCs) Have a Biological Role in Patients with Primary Myelofibrosis. Cancers 16 (14) (2024)
Giovanni Barosi, Rita Campanelli, Paolo Catarsi, Carlotta Abbà, Adriana Carolei, Margherita Massa, Robert Peter Gale, Vittorio Rosti
Type 1 CALR mutation allele frequency correlates with CD34/CXCR4 expression in myelofibrosis-type megakaryocyte dysplasia: A mechanism of disease progression? Blood cancer journal 14 (1) (2024)
Rita Campanelli, Adriana Carolei, Paolo Catarsi, Carlotta Abbà, Emanuela Boveri, Marco Paulli, Raffaele Gentile, Monica Morosini, Riccardo Albertini, Stefania Mantovani, Margherita Massa, Giovanni Barosi, Vittorio Rosti
Circulating Polymorphonuclear Myeloid-Derived Suppressor Cells (PMN-MDSCs) Have a Biological Role in Patients with Primary Myelofibrosis. Cancers 16 (14) (2024)
Giovanni Barosi, Paolo Catarsi, Rita Campanelli, Margherita Massa, Adriana Carolei, Carlotta Abbà, Annalisa de Silvestri, Robert Peter Gale, Vittorio Rosti
VEGFA rs3025039 is associated with phenotype severity of myelofibrosis-type megakaryocyte dysplasia. EJHaem 4 (3) (2023)
Giovanni Barosi, Vittorio Rosti, Robert Peter Gale
Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives. Leukemia (2023)
Giovanni Barosi, Vittorio Rosti, Robert Peter Gale
JAK2V617F and ischemic stroke: CHIP or CMD-NBV? Blood advances (2023)
Giovanni Barosi, Robert Peter Gale
Everyone is entitled to his or her own opinion but not to their own facts. British journal of haematology 196 (6) (2022)
Giovanni Barosi, Robert Peter Gale
Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story. Blood advances 6 (7) (2022)
Laura Villani, Adriana Carolei, Vittorio Rosti, Margherita Massa, Rita Campanelli, Paolo Catarsi, Carlotta Abbà, Robert Peter Gale, Giovanni Barosi
Clinical Relevance of VEGFA (rs3025039) +936 C>T Polymorphism in Primary Myelofibrosis: Susceptibility, Clinical Co-Variates, and Outcomes. Genes 12 (8) (2021)
Elena Masselli, Cecilia Carubbi, Giulia Pozzi, Antonio Percesepe, Rita Campanelli, Laura Villani, Giuliana Gobbi, Sabrina Bonomini, Giovanni Roti, Vittorio Rosti, Margherita Massa, Giovanni Barosi, Marco Vitale
Impact of the rs1024611 Polymorphism of CCL2 on the Pathophysiology and Outcome of Primary Myelofibrosis. Cancers 13 (11) (2021)
Rita Campanelli, Margherita Massa, Vittorio Rosti, Giovanni Barosi
New Markers of Disease Progression in Myelofibrosis. Cancers 13 (21) (2021)
Laura Villani, Vittorio Rosti, Margherita Massa, Rita Campanelli, Paolo Catarsi, Adriana Carolei, Carlotta Abbà, Annalisa de Silvstri, Robert Peter Gale, Giovanni Barosi
VEGFA rs3025020 Polymorphism Contributes to CALR -Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis. TH open : companion journal to thrombosis and haemostasis 5 (4) (2021)
Giovanni Barosi, Vittorio Rosti, Paolo Catarsi, Laura Villani, Carlotta Abbà, Adriana Carolei, Umberto Magrini, Robert Peter Gale, Margherita Massa, Rita Campanelli
Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis. Leukemia 35 (2) (2020)
Alessandra Carobbio, Alberto Ferrari, Arianna Masciulli, Arianna Ghirardi, Giovanni Barosi, Tiziano Barbui
Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood advances 3 (11) (2020)
Onima Chowdhury, Jennifer O'Sullivan, Nikolaos Barkas, Guanlin Wang, Gemma Buck, Angela Hamblin, Ayalew Tefferi, Haifa K Al-Ali, Giovanni Barosi, Timothy Devos, Heinz Gisslinger, Qian Jiang, Jean-Jacques Kiladjian, Ruben Mesa, Francesco Passamonti, Vincent Ribrag, Gary Schiller, Alessandro M Vannucchi, Daobin Zhou, Mary Frances Frances McMullin, Jianhua Zhong, Robert Peter Gale, Adam J Mead, null null
Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide. Leukemia 35 (4) (2020)
Giada Rotunno, Carmela Mannarelli, Giada Brogi, Annalisa Pacilli, Francesca Gesullo, Francesco Mannelli, Sara Fiaccabrino, Benedetta Sordi, Chiara Paoli, Ilaria Marone, Elisa Rumi, Rossella Manfredini, Giovanni Barosi, Mario Cazzola, Alessandro Maria Maria Vannucchi, Paola Guglielmelli
Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation. Blood 133 (26) (2019)